Prostate Cancer Trial, Recruiting (NCT05443412)

Prostate Cancer Trial, Recruiting NCT05443412 Sponsor: Chinese University of Hong Kong Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05443412 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Men aged 18 or older
People where doctors suspect prostate cancer may be present
People with a prostate-specific antigen (PSA) blood test result between 4 and 20 ng/mL
People whose rectal examination results suggest the cancer, if present, appears to be contained within the prostate gland
People who are able to give written consent to participate

Who may not be able to join:

People who have previously had a prostate biopsy
People with a past or current diagnosis of prostate cancer
People for whom an MRI scan is not medically suitable (for example, those with a pacemaker fitted or who experience severe claustrophobia)
People for whom a transperineal prostate biopsy procedure is not medically suitable — this includes those with an active urinary tract infection, certain positioning or physical limitations, uncorrectable blood clotting problems, or those taking blood-thinning or anti-clotting medications that cannot be safely stopped (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Ka-Fung CHIU, FRCS, PhD, Chinese University of Hong Kong

Phone: 35052625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05443412

Sponsor: Chinese University of Hong Kong

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 35052625

More information: https://clinicaltrials.gov/study/NCT05443412

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Men aged 18 or older
People where doctors suspect prostate cancer may be present
People with a prostate-specific antigen (PSA) blood test result between 4 and 20 ng/mL
People whose rectal examination results suggest the cancer, if present, appears to be contained within the prostate gland
People who are able to give written consent to participate

Who may not be able to join:

People who have previously had a prostate biopsy
People with a past or current diagnosis of prostate cancer
People for whom an MRI scan is not medically suitable (for example, those with a pacemaker fitted or who experience severe claustrophobia)
People for whom a transperineal prostate biopsy procedure is not medically suitable — this includes those with an active urinary tract infection, certain positioning or physical limitations, uncorrectable blood clotting problems, or those taking blood-thinning or anti-clotting medications that cannot be safely stopped (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chinese University of Hong Kong

Registry

ClinicalTrials.gov

Start date

1 August 2023

Est. completion

31 July 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Diagnosis of clinically significant Prostate cancer (csPCa); • csPCa is diagnosis of ISUP Grade group ≥2 prostate cancer in at least 1 biopsy core

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov